Related content

Naftopidil for the treatment of benign prostate hyperplasia: a systematic review

By Castiglione Fabio   Benigni Fabio   Briganti Alberto   Salonia Andrea   Villa Luca   Nini Alessandro   Di Trapani Ettore   Capitanio Umberto   Hedlund Petter   Montorsi Francesco  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 719-732

Informa Healthcare

Access to resources Recommend Favorite

Risk Factors for Benign Prostatic Hyperplasia in South Korean Men

By  

Urologia Internationalis, Vol. 76, Iss. 1, 2006-01 ,pp. : 11-19

Karger

Access to resources Recommend Favorite

Efficacy of Doxazosin in the Treatment of Acute Urinary Retention due to Benign Prostate Hyperplasia

By  

Urologia Internationalis, Vol. 81, Iss. 1, 2008-07 ,pp. : 66-71

Karger

Access to resources Recommend Favorite

Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once‐daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double‐blind, placebo‐controlled, clinical trials

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 12, 2015-12 ,pp. : 1496-1507

John Wiley & Sons Inc

Access to resources Recommend Favorite

Presence of PSA auto‐antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis)

By  

ANDROLOGIA (ELECTRONIC), Vol. 47, Iss. 3, 2015-04 ,pp. : 328-332

John Wiley & Sons Inc

Access to resources Recommend Favorite